Study: NCT01599494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8962
Description: MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recFSH
Description: Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recFSH
Description: Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: 0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: 0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human Chorionic Gonadotropin (hCG)
Description: Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human Chorionic Gonadotropin (hCG)
Description: Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.